相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome
Chen Li et al.
JAMA DERMATOLOGY (2021)
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
William Damsky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis
Jingshi Wang et al.
HAEMATOLOGICA (2020)
Treatment of atopic dermatitis with ruxolitinib cream (JAKI/JAK2 inhibitor) or triamcinolone cream
Brian S. Kim et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
E. L. Simpson et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
Pablo Olivera et al.
GASTROENTEROLOGY (2020)
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Treatment of severe lichen planus with the JAK inhibitor tofacitinib
William Damsky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea
William Damsky et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report
Doyoung Kim et al.
NATURE MEDICINE (2020)
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
Madan Jagasia et al.
BLOOD (2020)
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
William J. Sandborn et al.
JOURNAL OF CROHNS & COLITIS (2020)
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease
Azucena Salas et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
Jonathan Silverberg et al.
JAMA DERMATOLOGY (2020)
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
David Rosmarin et al.
LANCET (2020)
Janus Kinase Inhibition in the Aicardi-Goutieres Syndrome
Adeline Vanderver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib
Wenxia Wang et al.
JOURNAL OF SCLERODERMA AND RELATED DISORDERS (2020)
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis
Stephen Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
Masayoshi Harigai
RHEUMATOLOGY (2019)
Janus kinases to jakinibs: from basic insights to clinical practice
Massimo Gadina et al.
RHEUMATOLOGY (2019)
Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
Christopher Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib
Michael Levraut et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
William J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results
Martay Gonzalez Vicent et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Hepatic growth hormone-JAK2-STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression
Doris Kaltenecker et al.
CYTOKINE (2019)
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Peter C. Taylor et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience
Inuk Zandvakili et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Ian C. Scott et al.
DRUG SAFETY (2018)
Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians
Aprajita Jagpal et al.
DRUG SAFETY (2018)
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Gina A. Montealegre Sanchez et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Massimo Gadina et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment
Kevin L. Winthrop et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Topical Janus kinase inhibitors: A review of applications in dermatology
Anna-Marie Hosking et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+and CD8+memory T-cells
C. Enerback et al.
SCIENTIFIC REPORTS (2018)
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Przemyslaw J. Kotyla
BIOMED RESEARCH INTERNATIONAL (2018)
Tofacitinib for the treatment of psoriasis and psoriatic arthritis
Anna Berekmeri et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Nikolas von Bubnoff et al.
BMC CANCER (2018)
Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia
Cecile Rotenberg et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
William Damsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma
Hart S. Dengler et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors
Abril Verden et al.
DRUG SAFETY (2018)
The JAK2 pathway is activated in idiopathic pulmonary fibrosis
Javier Milara et al.
RESPIRATORY RESEARCH (2018)
The hygiene hypothesis in autoimmunity: the role of pathogens and commensals
Jean-Francois Bach
NATURE REVIEWS IMMUNOLOGY (2018)
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
Julian Panes et al.
GUT (2017)
Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway
Liu-Ya Tang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib
Brett King et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Tofacitinib for the treatment of alopecia areata and variants in adolescents
Brittany G. Craiglow et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
JAK inhibitors in dermatology: The promise of a new drug class
William Damsky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
Nicolino Ruperto et al.
PEDIATRIC RHEUMATOLOGY (2017)
Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis
Debomita Chakraborty et al.
NATURE COMMUNICATIONS (2017)
Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease
C. Hurabielle et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis
Larisa Broglie et al.
BLOOD ADVANCES (2017)
An Overview of Hemophagocytic Lymphohistiocytosis
Ysabella M. Esteban et al.
PEDIATRIC ANNALS (2017)
A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease
Ahmad Kheirkhah et al.
CORNEA (2017)
Mechanisms and consequences of Jak-STAT signaling in the immune system
Alejandro V. Villarino et al.
NATURE IMMUNOLOGY (2017)
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Jeffrey R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Hypereosinophilic Syndrome
Casey Curtis et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2016)
IFN-γ-Producing T-Helper 17.1 Cells Are Increased in Sarcoidosis and Are More Prevalent than T-Helper Type 1 Cells
Joris Ramstein et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
Jeffrey R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
Rupali Das et al.
BLOOD (2016)
Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice
Sophia Maschalidi et al.
BLOOD (2016)
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
Megan E. B. Clowse et al.
DRUG SAFETY (2016)
JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus
Joerg Wenzel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment
Drew J. B. Kurtzman et al.
JAMA DERMATOLOGY (2016)
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Milene Kennedy Crispin et al.
JCI INSIGHT (2016)
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
S. J. Thomas et al.
BRITISH JOURNAL OF CANCER (2015)
Human autoimmune diseases: a comprehensive update
Lifeng Wang et al.
JOURNAL OF INTERNAL MEDICINE (2015)
Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model (vol 135, pg 1912, 2015)
Emilie S. Chan et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R. Zeiser et al.
LEUKEMIA (2015)
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Tofacitinib Citrate for the Treatment of Vitiligo A Pathogenesis-Directed Therapy
Brittany G. Craiglow et al.
JAMA DERMATOLOGY (2015)
Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations
Joshua D. Milner et al.
BLOOD (2015)
Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
Brittany G. Craiglow et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Luzhou Xing et al.
NATURE MEDICINE (2014)
CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo
Mehdi Rashighi et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
Stanley Cohen et al.
ARTHRITIS & RHEUMATOLOGY (2014)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
John J. O'Shea et al.
IMMUNITY (2012)
Diagnostic Accuracy of a Specific Cytokine Pattern in Hemophagocytic Lymphohistiocytosis in Children
Xiao-Jun Xu et al.
JOURNAL OF PEDIATRICS (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Hyperimmunoglobulin E syndromes in pediatrics
Qian Zhang et al.
CURRENT OPINION IN PEDIATRICS (2011)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Commentary: Treatment of Telangiectasia-An Editorial
Ronald G. Wheeland
DERMATOLOGIC SURGERY (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Crosstalk among Jak-STAT, toll-like receptor, and ITAM-dependent pathways in macrophage activation
Xiaoyu Hu et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Anti-IL-5 and hypereosinophilic syndromes
SA Sutton et al.
CLINICAL IMMUNOLOGY (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
IL-13 receptors and signaling pathways: An evolving web
GKK Hershey
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study
MF Doran et al.
ARTHRITIS AND RHEUMATISM (2002)
分享论文
